Incyte Provides Update on Parsaclisib and MCLA-145

WILMINGTON, Del.--(BUSINESS WIRE) January 25, 2022 -- Incyte (Nasdaq:INCY) today announced updates regarding the clinical development of parsaclisib, the Company’s next-generation oral inhibitor of phosphatidylinositol 3-kinase delta...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news